This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Besponsa® (inotuzumab ozogamicin) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Download clinical papers and access the Guidelines

Use the links below to access Besponsa clinical papers

1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukaemia; Kantarjian HM et al. NEJM 2016; 375: 740-753
Link to download paper

This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0370. March 2020​​​​​​​

2. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review; Kebriaei P, et al. Bone Marrow Transplant 2018;53:449–456
Link to download paper​​​​​​​

This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0369. March 2020​​​​​​​

3. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment; Marks DI et al. Cancer Medicine. 2019;8 :5959-5968.
Link to download paper​​​​​​​

This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0365. March 2020

Besponsa Clinical Papers

NICE Recommended1:

BESPONSA® (inotuzumab oxogamicin) is recommended as an option for treating relapsed or refractory CD22-positive B-call precursor acute lymphoblastic leukaemia in adults. People with relapsed or refractory Philadelphia chromosome positive disease should have had at least 1 tyrosine kinase inhibitor.

Learn more

Scottish Medicine Consortium (SMC)2

Advice: following a full submission assessed under the ultra-orphan and end of life medicine process: ​​​​​​​

  • inotuzumab ozogamicin (BESPONSA®) is accepted for restricted use within NHS Scotland.
  • Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor.
  • SMC restriction: in patients for whom the intent is to proceed to stem cell transplantation.
  • A phase III open label randomised controlled study demonstrated improvements in remission rates and overall survival for the patient population under review when treated with inotuzumab ozogamicin compared with standard chemotherapy.
  • This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of inotuzumab ozogamicin. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting
Learn More

Guidelines

Developments in Leukaemia Care 

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Management of Refractory/Relapsed ALL 

Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease

Learn More

NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium
 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References
  1. NICE Technology Appraisal Guidance (TA541). Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Available at: https://www.nice.org.uk/guidance/TA541 Published: 19 September 2018. [accessed March 2021].
  2. Scottish Medicines Consortium. Inotuzumab ozogamicin (BESPONSA): 1328/18 (Published: 11 June 2018). Available at: https://www.scottishmedicines.org.uk/medicines-advice/inotuzumab-ozogamicin-besponsa-fullsubmission-132818/ [accessed March 2021].​​​​​​​
PP-INO-GBR-0394. March 2021

Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.

Download here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No